Clinical Trial Highlights

• AURELIA Analysis Shows Benefits of Bevacizumab as Add-on Therapy in Ovarian Cancer
• Results and Subgroup Analyses of the PETACC-8 Trial
• Single-Agent Doxorubicin versus Doxorubicin Plus Ifosfamide in Advanced Soft Tissue Sarcoma
• The Efficacy and Safety of Docetaxel Plus Prednisone with or without Lenalidomide in Patients with Castrate-Resistant Prostate Cancer: The MAINSAIL Trial
• Two Years versus One Year of Trastuzumab in Patients with Early Breast Cancer
• Adjuvant Trastuzumab for 6 versus 12 Months in Patients with Early Breast Cancer
• Breast Cancer: Updated Overall Survival Results from EMILIA
• Phase 3 Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK-Positive NSCLC
• CORRECT Trial of Regorafenib in Metastatic Colorectal Cancer: Overall Survival Update